5:49 PM
 | 
Dec 26, 2012
 |  BC Extra  |  Company News

Infinity, Takeda amend PI3K deal

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) amended a 2010 deal on Monday under which Infinity has exclusive, worldwide rights to develop and commercialize Takeda's phosphoinositide-3-kinase ( PI3K) inhibitors, including lead compound IPI-145. Takeda received a $15 million payment from Infinity in exchange for waiving its...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >